Qiagen NV | QIA - Operating Expenses


Qiagen NV reported $418.54M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alaunos Therapeutics USD 1.01M 175K Mar/2026
argenx SE USD 904M 10.57M Mar/2026
Avita Medical AUD 28.02M 1.55M Dec/2025
Dianthus Therapeutics USD 47M 22.83M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
IQVIA Holdings USD 6.22B 4.53B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Organon & Co USD 903M 387M Mar/2026
Qiagen NV USD 418.54M 23.25M Dec/2025
Revvity USD 628.34M 2.12M Mar/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
Viatris USD 3.54B 323.9M Mar/2026
Xeris Pharmaceuticals USD 75.21M 6.18M Mar/2026